Although we have not formally quantified synergy, the enhanced anti-tumor activity seen with prior SLAMF7 co-stimulation and PD-1/PD-L1 blockade underscores that dual targeting of co-stimulatory and inhibitory pathways is beneficial, irrespective of whether the interaction is strictly additive or synergistic. Here, CD274 is linked to neoplasm.